Walleye Capital LLC Arrowhead Pharmaceuticals, Inc. Call Options Transaction History

Walleye Capital LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$19.36 - $29.54 $174,240 - $265,860	-9,000 Reduced 61.64%	5,600 $108,000
Q2 2024 Aug 14, 2024	BUY	$21.87 - $28.24 $319,302 - $412,304	14,600 New	14,600 $379,000
Q2 2023 Aug 14, 2023	SELL	$25.16 - $41.38 $221,408 - $364,144	-8,800 Reduced 84.62%	1,600 $57,000
Q1 2023 May 15, 2023	BUY	$23.68 - $38.51 $222,592 - $361,994	9,400 Added 940.0%	10,400 $264,000
Q4 2022 Feb 14, 2023	BUY	$28.0 - $40.56 $28,000 - $40,560	1,000 New	1,000 $40,000
Q1 2020 May 15, 2020	SELL	$20.56 - $63.12 $402,976 - $1.24 Million	-19,600 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$28.14 - $73.01 $81,606 - $211,729	2,900 Added 17.37%	19,600 $1.24 Million
Q3 2019 Nov 14, 2019	BUY	$26.26 - $34.86 $438,542 - $582,162	16,700 New	16,700 $471,000
Q2 2019 Aug 14, 2019	SELL	$17.43 - $28.82 $170,814 - $282,436	-9,800 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$12.05 - $20.18 $118,090 - $197,764	9,800 New	9,800 $180,000

294

90.8M

155K

426K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.08B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.